RxDoctor Payments Data

Michael Stagner, MD

Ophthalmology · Lake Havasu City, AZNPI 1720069982

Payments from drug & device makers

$987in general payments, 2019–2025

Across 41 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$156
  • Alcon$147
  • AbbVie$134
  • Bausch & Lomb Americas Inc.$123
  • Rxsight Inc$109
  • Sun Pharmaceutical Industries Inc.$109
  • plus $209 from 7 others

What the payments were for

  • Food & beverage$987100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$987 in reported general payments places this provider in the 35th percentile of 310 ophthalmology providers in Arizona.

See all ophthalmology providers in Arizona

Medicare billing

Part B allowed, 2024
$166,823
Medicare patients
778
Services billed
1,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine26$21,087
LumiganBimatoprost19$12,055
CombiganBrimonidine Tartrate/Timolol11$6,258
Ketorolac Tromethamine91$4,817
Latanoprost438$4,817
Brimonidine Tartrate139$4,534
Prednisolone Acetate78$3,635
MoxifloxacinMoxifloxacin Hcl75$2,892
ErythromycinErythromycin Base180$2,576
Brinzolamide15$2,477
Timolol Maleate163$2,298
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$2,172
Dorzolamide Hcl85$1,613
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat71$875
Doxycycline Hyclate66$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$134$39,39956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 310 ophthalmology providers in Arizona.

Other ophthalmology in Lake Havasu City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →